Thrombocytopenia in cardiovascular patients has specific etiologies, notably heparin and GP IIb/IIIa inhibitors, requiring careful management to prevent thromboembolic complications like HIT.
Answers are grounded in this paper and cite their sources.
Requires HIT consideration in ICU thrombocytopenia to avert thromboembolism; leaves open etiology-specific trials in cardiovascular patients.
Copyright: © 2015 Sinan UY. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Thrombocytopenia is a common problem in cardiovascular patients. The aetiology and management may be different than those in other populations. The drugs that are used during percutaneous coronary interventions most commonly associated with thrombocytopenia are the glycoprotein (GP) IIb/IIIa receptor inhibitors and heparin. Thienopyridines rarely cause thrombocytopenia. The platelet count falls, primarily due to platelet damage and destruction in the bypass circuit and hemodilution after open-heart surgery. Heparin is the most common drug to be implicated in thrombocytopenia in intensive care unit patients. Determining the etiology for the low platelet count is important for the implementation of appropriate management. Heparin‐induced thrombocytopenia is a potentially devastating immune mediated adverse drug reaction caused by the emergence of antibodies that activate platelets in the presence of heparin. Despite thrombocytopenia, bleeding is rare; rather, HIT is strongly associated with thromboembolic complications involving both the arterial and venous systems.
No takes yet. Share an insight, caveat, or question.
Ümit Yaşar Si̇nan (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: